Rural breast cancer deaths rise faster than urban rates, driven by low income, later diagnosis, and treatment gaps—warning of widening disparities by 2035.
|Articles|October 18, 2013
- B-Cell Malignancies
- Volume 1
- Issue 1
BTK and PI3K Inhibitors in Development for Chronic Lymphocytic Leukemia
Author(s)Mark Weiss, MD
Mark Weiss, MD, from the Kimmel Cancer Center at Jefferson, gives an overview of agents in development for chronic lymphocytic leukemia.
Advertisement
Mark Weiss, MD, from the Kimmel Cancer Center at Jefferson, gives an overview of agents in development for chronic lymphocytic leukemia, including BTK and PI3K inhibitors.
Therapy for CLL: Where Are We Today? Where Will We Be Tomorrow?
Articles in this issue
about 13 years ago
Updated Data for Pomalidomide in Relapsed/Refractory Multiple Myelomaabout 13 years ago
Clinical Advances in Mantle Cell Lymphomaabout 13 years ago
Emerging Therapies for the Treatment of Mantle Cell Lymphomaabout 13 years ago
In Brief: Phase III Trials in Multiple Myelomaabout 13 years ago
Therapy for CLL: Where Are We Today? Where Will We Be Tomorrow?about 13 years ago
Transforming Expectations and Outcomes With Targeted Therapiesabout 13 years ago
The Utility of Pomalidomide in R/R Multiple Myelomaabout 13 years ago
Dr. Zelenetz Discusses Diagnosis and Treatment Issues in Indolent NHLAdvertisement
Related to this article
The TASKIN trial found a 12-month overall survival rate of 61.3% with vilamakitug plus standard-of-care therapy, with exploratory findings suggesting potential benefit in right-sided tumors.
Lyudmila Bazhenova, MD, discusses the FDA’s expanded approval of taletrectinib for ROS1-positive non–small cell lung cancer.
UGN-103, a formulation of intravesical mitomycin as treatment for low-grade intermediate-risk non–muscle-invasive bladder cancer, will receive FDA review with a PDUFA date of June 14, 2027.
FDA approves dostarlimab for MSI-H/dMMR locally advanced rectal cancer, driving high complete responses and helping many patients avoid surgery, radiation, and chemo.
SABR improved recurrence-free survival vs historical benchmark with IVC tumor thrombus; investigators hypothesize this could be used to reduce invasive surgery.
In patients 45+ with papillary thyroid cancer, men with dual BRAF V600E and TERT promoter mutations face sharply higher mortality, reshaping risk stratification.
Selpercatinib achieved a 53% objective response rate in pediatric patients with RET-altered solid tumors, with no treatment discontinuations due to treatment-related adverse events in LIBRETTO-121.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
Selpercatinib Shows Durable Responses in Pediatric Solid Tumors
3
Male Sex, Age, and Tumor Genetics Linked to Thyroid Cancer Mortality
4
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
5